To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

2/8/2025, 9:05 AM

Summary of Bill HR 1117

Bill 119 HR 1117, also known as the Direct-to-Consumer Drug Advertising Restriction Act, aims to make changes to the Federal Food, Drug, and Cosmetic Act in order to limit the advertising of prescription drugs directly to consumers.

The bill proposes that pharmaceutical companies would no longer be allowed to advertise prescription drugs directly to consumers through mediums such as television, radio, print, and online advertisements. Instead, the focus would shift to healthcare providers who would be responsible for informing patients about prescription drug options.

Proponents of the bill argue that direct-to-consumer drug advertising can lead to unnecessary prescriptions, increased healthcare costs, and potential harm to patients who may not fully understand the risks and benefits of the medications being advertised. By restricting these advertisements, the bill aims to promote more informed decision-making by patients and reduce the influence of marketing tactics on prescribing practices. Opponents of the bill, however, argue that direct-to-consumer drug advertising plays a valuable role in educating patients about treatment options and empowering them to have informed discussions with their healthcare providers. They also raise concerns about potential limitations on free speech and the impact on pharmaceutical companies' ability to communicate important information about their products. Overall, Bill 119 HR 1117 represents a significant proposal to regulate the advertising practices of pharmaceutical companies and could have far-reaching implications for the healthcare industry. It is currently under consideration in the US Congress and will continue to be debated and discussed in the coming months.

Current Status of Bill HR 1117

Bill HR 1117 is currently in the status of Bill Introduced since February 7, 2025. Bill HR 1117 was introduced during Congress 119 and was introduced to the House on February 7, 2025.  Bill HR 1117's most recent activity was Referred to the House Committee on Energy and Commerce. as of February 7, 2025

Bipartisan Support of Bill HR 1117

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 1117

Primary Policy Focus

Alternate Title(s) of Bill HR 1117

To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.
Start holding our government accountable!

Comments

Sponsors and Cosponsors of HR 1117

Rosa L. DeLauro
Rosa L. DeLauro
Connecticut(Democrat)

Latest Bills

Restore Protections for Dialysis Patients Act
Bill HR 2199March 29, 2025
No Tax on LOSAP Act
Bill HR 2279March 29, 2025
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Bill HR 2148March 29, 2025
BO’s Act
Bill HR 2168March 29, 2025
SIGN Pardons Act
Bill HR 2248March 29, 2025
Cerebral Palsy Research Program Authorization Act of 2025
Bill HR 2178March 29, 2025
Pilot Certificate Accessibility Act
Bill HR 2247March 29, 2025
Improving VA Training for Military Sexual Trauma Claims Act
Bill HR 2201March 29, 2025
Recycling Infrastructure and Accessibility Act of 2025
Bill HR 2145March 29, 2025
Spectrum Coordination Act
Bill HR 2171March 29, 2025